CO

Cencora, Inc.

CORHealthcareNASDAQ

Medical Distribution

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$321.33B
+9.3% YoY
Net Income
$1.55B
+3.0% YoY
EBITDA
$3.75B
+11.1% YoY
Free Cash Flow
$2.04B

Scan Results

Daily timeframe
2 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Sep 3CONFIRMED MACD Positive CrossoverHistogram +0.7406, positive momentum
RSI OverboughtRSI 78.1, above 70, stock may be overbought
Sep 2 MACD Positive CrossoverHistogram +0.1932, positive momentum
About Cencora, Inc.

Part of the healthcare sector, Cencora, Inc. (COR) is listed under Medical Distribution. The company carries a $63.15B market cap, placing it firmly in the large-cap category.

Where COR stands vs its 150-day and 200-day moving averages

As of the September 3, 2026 close, COR finished 7.68% above its 150-day moving average ($312.36) and 4.79% above its 200-day moving average ($320.98). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is COR overbought or oversold?

At the September 3, 2026 close, COR's RSI(14) was 78.1, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$63.15B
P/E (TTM)24.57
Fwd P/E16.73
EPS$13.47
Beta0.57
52W Change+10.8%
Dividend Yield0.73%
ROE96.9%
Analysis

The company holds $2.82B in cash, though total debt stands at $14.46B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $2.04B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 96.9%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 3.6% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $238.59B (2022) to $321.33B (2025), reflecting a 35% increase over the period.

With a beta below 0.7, Cencora, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Cencora, Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Cencora, Inc.'s trajectory.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms